Drug intelligence / Profile preview

lamivudine + abacavir + tenofovir disoproxil fumarate + lopinavir + ritonavir

Development stage: Phase 4
Lead developer: Cipla
Modality: Small Molecules
Administration: Oral

Overview

A combination of five antiretroviral medications used in the treatment of HIV infection. This combination includes two nucleoside reverse transcriptase inhibitors (lamivudine and abacavir), one nucleotide reverse transcriptase inhibitor (tenofovir disoproxil fumarate), and two protease inhibitors (lopinavir and ritonavir, with ritonavir serving as a pharmacokinetic enhancer for lopinavir).

Targets

CYP3A4 (Cytochrome P450 3A4)CYP3A5 (Cytochrome P450 family 3 subfamily A member 5)HBV Pol (Hepatitis B virus polymerase)PR (Progesterone receptor)Human immunodeficiency virus type 1 reverse transcriptaseHLA-B*57:01 (Human leukocyte antigen B*57:01)

Beyond the preview

Go deeper on lamivudine + abacavir + tenofovir disoproxil fumarate + lopinavir + ritonavir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lamivudine + abacavir + tenofovir disoproxil fumarate + lopinavir + ritonavir.